More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA due to manufacturing and delivery concerns, the treatment has since redeemed itself by scoring a green ...

A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a ...

Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow ...

After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for the alpha-emitting isotope ...

A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...

Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...

Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics ...

As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...